48
1. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C; Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.Clin Infect Dis.2003;37:1405-1433.
2. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31:347-382. Epub 2000 Sep 07.
3. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. Dec 1 2004;39(11):1642-50. 4. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in
North American adults. Postgrad Med. Mar 2010;122(2):130-41
5. Amrita. Evaluasi penggunaan antibiotik empirik pada penderita Community-Acquired Pneumonia (CAP) yang dirawat di RSUP dr. Kariadi Semarang. Semarang: Universitas Diponegoro. 2010.
6. Brett J,Lam V, Baysari MT, Milder T, Killen L, Chau A, et al. Pneumonia severity scores and prescribing antibiotics for community-acquired
pneumonia at an Australian hospital Journal of Pharmacy Practice and Research, Vol. 43, No. 2, Jun 2013: 97-100.
7. Mocelin CA, Santos RP. Community-acquired Pneumonia at the Hospital de Clinicas de Porto Alegre: evaluation of a care protocol. Braz J Infec Dis.2013;17:511-5 - Vol. 17 Num.5 DOI: 10.1016/j.bjid.2012.11.013 8. Niederman MS, Mandell LA, Anzueto A, Bass, JB, Broughton WA,
Campbell GD, et al; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med.2001;163:1730-1754.
9. Lim I, Shaw DR, Stanley DP, et al. A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust 1989; 151: 87-91.
10. Currie BJ, Fisher DA, Howard DM, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 2000; 31: 981-986
11. Anstey NM, Currie BJ, Withnall KM. Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. Clin Infect Dis 1992; 14: 83-91.
12. File TM. Community-acquired pneumonia. Lancet 2003; 362:1991–2001. 13. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Summary
of Canadian Guideline for the Initial Management of Community-acquired Pneumonia : An evidence-based update by the Canadian Infectious
Disease Society and the Canadian Thoracic Society. Can J Infect Dis. 2000 Sep-Oct; 11(5): 237–248.
14. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG, Infectious Diseases Society of America, American Thoracic Society Clin Infect Dis.2007 Mar 1; 44 Suppl 2():S27-72.
15. Lim WS, Van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377–382.
16. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia.NEngl J Med 1997; 336:243–50.
17. Halm EA, Atlas SJ, Borowsky LH,Benzer TI, Metlay JP, Chang YC, and Singer DE. Understanding physician adherence with a pneumonia practice guideline: effects of patient, system, and physician factors. Arch Intern Med 2000; 160:98–104.
18. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 2005; 127:1260–70.
19. Goss CH, Rubenfeld GD, Park DR, Sherbin VL, Goodman MS, Root RK. Cost and incidence of social comorbidities in low-risk patients with
community-acquired pneumonia admitted to a public hospital.Chest 2003; 124:2148–55.
20. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003; 138:109–18.
21. Suchyta MR, Dean NC, Narus S, Hadlock CJ. Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. Am J Med 2001; 110:306–9.
22. Watkins RR, Lemonovich TL. Diagnosis and Management of
Community-Acquired Pneumonia in Adults. Am Fam
Physician. 2011 Jun 1;83(11):1299-1306.
23. Armitage K, Woodhead M; Lippincott Williams & Wilkins. New guidelines for the management of adult community-acquired pneumonia. Curr Opin Infect Dis 2007; 20:170–176.
24. Blot, S.I., Rodriguez, A., Solé-Violán, J., Blanquer, J., Almirall, J. and Rello, J. Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med 2007; 35: 2509–2514
25. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et
al. BTS guidelines for the management of community acquired pneumonia
in adults: update 2009. Thorax 2009;64:iii1-iii55 doi:10.1136/thx.2009.121434
26. Roson B, Carratala J,Dorca J, Casanova A, Manresa F, and Gudiol F. Etiology, Reasons for Hospitalization, Risk Classes, and Outcomes of Community-Acquired Pneumonia in Patients Hospitalized on the Basis of Conventional Admission Criteria. Clin Infect Dis 2001 Jul 15;33(2):158-65
27. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006; 27:151–7.
28. Ochoa-Gonder O, Vila-Corcoles A, Diego C, et al. The burden of CAP in the elderly: the Spanish Evan-65 study. BMC Public Health 2008; 8: 222– 222.
29. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005; 118:384–92
30. Surjanto E, Sutanto YS, Reviono, et al. Perbandingan Tiga Metode Prediksi secara Retrospektif dalam Menilai Derajat Pneumonia Komunitas pada Pasien Lanjut Usia di Rumah Sakit Dr. Moewardi Surakarta. J Respir Indo. 2013; 33:34-9
31. Shah BA, Ahmed W, Dhobi GN, et al. Validity of Pneumonia Severity Index and CURB-65 Severity Scoring Systems in Community Acquired Pneumonia in an Indian Setting. The Indian Journal of Chest Diseases & Allied Sciences 2010;Vol.52
Lampiran 1. Analisis univariat data responden Usia 21 30.9 30.9 30.9 47 69.1 69.1 100.0 68 100.0 100.0 <= 60 > 60 Total Valid
Frequency Percent Valid Percent
Cumulative Percent Jenis kelamin 33 48.5 48.5 48.5 35 51.5 51.5 100.0 68 100.0 100.0 Laki-laki Perempuan Total
Valid Frequency Percent Valid Percent
Cumulative Percent Tempat rawat 62 91.2 91.2 91.2 6 8.8 8.8 100.0 68 100.0 100.0 non-ICU ICU Total Valid
Frequency Percent Valid Percent
Cumulative Percent
Kelompok risiko PSI
1 1.5 1.5 1.5 4 5.9 5.9 7.4 9 13.2 13.2 20.6 31 45.6 45.6 66.2 23 33.8 33.8 100.0 68 100.0 100.0 I II III IV V Total Valid
Frequency Percent Valid Percent
Cumulative Percent PSI 14 20.6 20.6 20.6 31 45.6 45.6 66.2 23 33.8 33.8 100.0 68 100.0 100.0 rendah sedang tinggi Total Valid
Frequency Percent Valid Percent
Cumulative Percent
Keganasan
Frequency Percent Valid Percent
Cumulative Percent
Valid Ya 3 4.4 4.4 4.4
Tidak 65 95.6 95.6 100.0
Total 68 100.0 100.0
Total skor CURB
2 2.9 2.9 2.9 8 11.8 11.8 14.7 39 57.4 57.4 72.1 16 23.5 23.5 95.6 2 2.9 2.9 98.5 1 1.5 1.5 100.0 68 100.0 100.0 0 1 2 3 4 5 Total Valid
Frequency Percent Valid Percent
Cumulative Percent CURB 10 14.7 14.7 14.7 39 57.4 57.4 72.1 19 27.9 27.9 100.0 68 100.0 100.0 rendah sedang tinggi Total Valid
Frequency Percent Valid Percent
Cumulative Percent
penyakit liver
Frequency Percent Valid Percent
Cumulative Percent Valid Ya 3 4.4 4.4 4.4 Tidak 65 95.6 95.6 100.0 Total 68 100.0 100.0 CHF
Frequency Percent Valid Percent
Cumulative Percent Valid Ya 19 27.9 27.9 27.9 Tidak 49 72.1 72.1 100.0 Total 68 100.0 100.0 penyakit serebrovaskuler
Frequency Percent Valid Percent
Cumulative Percent
Valid Ya 10 14.7 14.7 14.7
Tidak 58 85.3 85.3 100.0
penyakit ginjal
Frequency Percent Valid Percent
Cumulative Percent Valid Ya 11 16.2 16.2 16.2 Tidak 57 83.8 83.8 100.0 Total 68 100.0 100.0 terapi empirik
Frequency Percent Valid Percent
Cumulative Percent Valid ceftriaxone 50 73.5 73.5 73.5 ciprofloxacin 3 4.4 4.4 77.9 levofloxacin 1 1.5 1.5 79.4 meropenem 2 2.9 2.9 82.4 cefotaxime 2 2.9 2.9 85.3 cefoperazone 1 1.5 1.5 86.8 ceftriaxone+ciprofloxacin 6 8.8 8.8 95.6 ceftriaxone+cefotaxime 1 1.5 1.5 97.1 ciprofloxacin+clindamycin 1 1.5 1.5 98.5 levofloxacin+meropenem 1 1.5 1.5 100.0 Total 68 100.0 100.0
Lampiran 2. Analisis bivariat data responden Crosstab 9 8 4 21 4.3 9.6 7.1 21.0 64.3% 25.8% 17.4% 30.9% 13.2% 11.8% 5.9% 30.9% 5 23 19 47 9.7 21.4 15.9 47.0 35.7% 74.2% 82.6% 69.1% 7.4% 33.8% 27.9% 69.1% 14 31 23 68 14.0 31.0 23.0 68.0 100.0% 100.0% 100.0% 100.0% 20.6% 45.6% 33.8% 100.0% Count Expected Count % within PSI % of Total Count Expected Count % within PSI % of Total Count Expected Count % within PSI % of Total <= 60 > 60 Usia Total
rendah sedang tinggi
PSI Total Chi-Square Tests 9.654a 2 .008 9.163 2 .010 7.801 1 .005 68 Pearson Chi-Square Likelihood Ratio Linear-by-Linear Association N of Valid Cases Value df Asymp. Sig. (2-sided)
1 cells (16.7%) have expected count less than 5. The minimum expected count is 4.32.
Crosstab 8 12 1 21 3.1 12.0 5.9 21.0 80.0% 30.8% 5.3% 30.9% 11.8% 17.6% 1.5% 30.9% 2 27 18 47 6.9 27.0 13.1 47.0 20.0% 69.2% 94.7% 69.1% 2.9% 39.7% 26.5% 69.1% 10 39 19 68 10.0 39.0 19.0 68.0 100.0% 100.0% 100.0% 100.0% 14.7% 57.4% 27.9% 100.0% Count Expected Count % within CURB % of Total Count Expected Count % within CURB % of Total Count Expected Count % within CURB % of Total <= 60 > 60 Usia Total
rendah sedang tinggi
CURB Total Chi-Square Tests 17.145a 2 .000 18.081 2 .000 15.875 1 .000 68 Pearson Chi-Square Likelihood Ratio Linear-by-Linear Association N of Valid Cases Value df Asymp. Sig. (2-sided)
1 cells (16.7%) have expected count less than 5. The minimum expected count is 3.09.
Crosstab 7 13 13 33 6.8 15.0 11.2 33.0 50.0% 41.9% 56.5% 48.5% 10.3% 19.1% 19.1% 48.5% 7 18 10 35 7.2 16.0 11.8 35.0 50.0% 58.1% 43.5% 51.5% 10.3% 26.5% 14.7% 51.5% 14 31 23 68 14.0 31.0 23.0 68.0 100.0% 100.0% 100.0% 100.0% 20.6% 45.6% 33.8% 100.0% Count Expected Count % within PSI % of Total Count Expected Count % within PSI % of Total Count Expected Count % within PSI % of Total Laki-laki Perempuan Jenis kelamin Total
rendah sedang tinggi PSI Total Chi-Square Tests 1.140a 2 .566 1.144 2 .565 .294 1 .588 68 Pearson Chi-Square Likelihood Ratio Linear-by-Linear Association N of Valid Cases Value df Asymp. Sig. (2-sided)
0 cells (.0%) have expected count less than 5. The minimum expected count is 6.79.
Crosstab 4 20 9 33 4.9 18.9 9.2 33.0 40.0% 51.3% 47.4% 48.5% 5.9% 29.4% 13.2% 48.5% 6 19 10 35 5.1 20.1 9.8 35.0 60.0% 48.7% 52.6% 51.5% 8.8% 27.9% 14.7% 51.5% 10 39 19 68 10.0 39.0 19.0 68.0 100.0% 100.0% 100.0% 100.0% 14.7% 57.4% 27.9% 100.0% Count Expected Count % within CURB % of Total Count Expected Count % within CURB % of Total Count Expected Count % within CURB % of Total Laki-laki Perempuan Jenis kelamin Total
rendah sedang tinggi CURB Total Chi-Square Tests .420a 2 .811 .422 2 .810 .057 1 .812 68 Pearson Chi-Square Likelihood Ratio Linear-by-Linear Association N of Valid Cases Value df Asymp. Sig. (2-sided)
1 cells (16.7%) have expected count less than 5. The minimum expected count is 4.85.
PSI * CURB Crosstabulation
Count
CURB
Total rendah sedang tinggi
PSI rendah 8 5 1 14
sedang 1 24 6 31
tinggi 1 10 12 23
Total 10 39 19 68
Reliability
Scale: ALL VARIABLES
Case Processing Summary
68 100.0 0 .0 68 100.0 Valid Excludeda Total Cases N %
Listwise deletion based on all variables in the procedure. a.
Reliability Statistics
.691 2
Cronbach's
ANOVA 48.618 67 .726 .000 1 .000 .000 1.000 15.000 67 .224 15.000 68 .221 63.618 135 .471 Between People Between Items Residual Total Within People Total Sum of
Squares df Mean Square F Sig
Grand Mean = 2.13
Intraclass Correlation Coefficient
.528b .333 .680 3.241 67.0 67 .000
.691c .500 .810 3.241 67.0 67 .000
Single Measures Average Measures
Intraclass
Correlationa Lower Bound Upper Bound 95% Confidence Interval
Value df1 df2 Sig
F Test with True Value 0
Two-way mixed effects model where people effects are random and measures effects are fixed.
Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the denominator variance.
a.
The estimator is the same, whether the interaction effect is present or not. b.
This estimate is computed assuming the interaction effect is absent, because it is not estimable otherwise. c.
terapi empirik * Tempat rawat Crosstabulation
Tempat rawat
Total non-ICU ICU
terapi empirik ceftriaxone Count 47 3 50
% of Total 69.1% 4.4% 73.5% ciprofloxacin Count 3 0 3 % of Total 4.4% .0% 4.4% Levofloxacin Count 0 1 1 % of Total .0% 1.5% 1.5% Meropenem Count 1 1 2 % of Total 1.5% 1.5% 2.9% Cefotaxime Count 2 0 2 % of Total 2.9% .0% 2.9% cefoperazone Count 1 0 1 % of Total 1.5% .0% 1.5% ceftriaxone+ciprofloxacin Count 5 1 6 % of Total 7.4% 1.5% 8.8% ceftriaxone+cefotaxime Count 1 0 1 % of Total 1.5% .0% 1.5%
ciprofloxacin+clindamycin Count 1 0 1 % of Total 1.5% .0% 1.5% levofloxacin+meropenem Count 1 0 1 % of Total 1.5% .0% 1.5% Total Count 62 6 68 % of Total 91.2% 8.8% 100.0%
terapi empirik * CURB Crosstabulation
CURB
Total rendah sedang tinggi
terapi empirik Ceftriaxone Count 8 28 14 50
% of Total 11.8% 41.2% 20.6% 73.5% Ciprofloxacin Count 0 3 0 3 % of Total .0% 4.4% .0% 4.4% Levofloxacin Count 0 1 0 1 % of Total .0% 1.5% .0% 1.5% Meropenem Count 1 1 0 2 % of Total 1.5% 1.5% .0% 2.9%
Cefotaxime Count 0 1 1 2 % of Total .0% 1.5% 1.5% 2.9% cefoperazone Count 0 0 1 1 % of Total .0% .0% 1.5% 1.5% ceftriaxone+ciprofloxacin Count 1 2 3 6 % of Total 1.5% 2.9% 4.4% 8.8% ceftriaxone+cefotaxime Count 0 1 0 1 % of Total .0% 1.5% .0% 1.5% ciprofloxacin+clindamycin Count 0 1 0 1 % of Total .0% 1.5% .0% 1.5% levofloxacin+meropenem Count 0 1 0 1 % of Total .0% 1.5% .0% 1.5% Total Count 10 39 19 68 % of Total 14.7% 57.4% 27.9% 100.0%
Lampiran 3. Spreadsheet
No
Nomer
cm Usia Sex Rawat PSI der.PSI
CURB-65 der.CURB 1 c374377 2 1 2 5 3 4 3 2 C373947 2 1 1 5 3 2 2 3 484757 2 2 1 4 2 2 2 4 c377238 2 1 1 5 3 3 3 5 c383888 2 1 1 2 1 2 2 6 c386336 2 1 1 5 3 5 3 7 c371174 2 2 1 5 3 2 2 8 b371770 2 1 1 4 2 2 2 9 c387630 2 2 1 5 3 2 2 10 c366531 1 2 1 2 1 0 1 11 c377370 1 1 1 3 1 2 2 12 c374186 1 2 1 1 1 0 1 13 c384952 2 1 2 5 3 3 3 14 c430487 2 2 1 5 3 3 3 15 c392798 2 2 2 5 3 4 3 16 b377418 2 2 1 4 2 2 2 17 c398081 2 2 1 4 2 2 2 18 c052585 2 2 1 4 2 2 2 19 b148605 1 1 1 4 2 2 2 20 c268084 1 2 1 3 1 1 1 21 c124793 2 1 1 5 3 2 2 22 c427502 1 2 2 2 1 1 1 23 c428852 2 2 1 5 3 3 3 24 c421710 2 2 1 4 2 3 3 25 c214179 2 1 1 4 2 2 2 26 c400199 2 1 1 4 2 2 2 27 c397469 1 1 1 5 3 2 2 28 c225469 2 1 1 3 1 3 3 29 c397568 1 1 1 4 2 2 2 30 c243988 2 2 1 5 3 2 2 31 c426718 2 2 1 4 2 2 2 32 c273637 2 2 1 4 2 2 2 33 c416097 2 2 1 5 3 2 2
Nomer
cm Usia Sex Rawat PSI der.psi
CURB-65 der.CURB 34 c417197 2 2 1 4 2 2 2 35 c427437 2 1 1 5 3 3 3 36 c404497 1 2 1 2 1 1 1 37 c428997 2 2 1 5 3 3 3 38 c291567 2 2 1 4 2 2 2 39 c204117 2 1 1 4 2 3 3 40 c422706 2 2 1 4 2 2 2 41 c340066 2 1 1 4 2 2 2 42 c122806 2 1 1 5 3 3 3 43 b274925 2 1 1 3 1 1 1 44 c414835 2 2 1 4 2 3 3 45 c205875 1 2 1 4 2 2 2 46 c424255 1 1 1 4 2 3 3 47 c385434 2 2 1 5 3 3 3 48 c287864 1 1 1 5 3 1 1 49 c393824 1 2 1 3 1 2 2 50 c429414 2 1 1 4 2 2 2 51 c389513 1 1 2 5 3 2 2 52 c396233 1 2 1 4 2 1 1 53 c109693 1 2 1 4 2 2 2 54 c422472 2 1 1 3 1 2 2 55 c343112 2 1 1 4 2 2 2 56 c418952 1 2 1 3 1 2 2 57 b428322 1 1 1 3 1 1 1 58 c413152 2 2 1 4 2 3 3 59 c404311 2 1 1 4 2 2 2 60 b186461 1 2 1 4 2 2 2 61 c415130 1 1 1 5 3 2 2 62 b369240 2 1 1 5 3 2 2 63 c426800 2 1 1 3 1 1 1 64 c364230 1 1 2 4 2 2 2 65 c428429 2 2 1 4 2 3 3 66 c396968 2 2 1 4 2 2 2 67 c384489 2 1 1 4 2 2 2 68 c083541 2 2 1 5 3 3 3
No
Nomer
cm terapi keganasan liver chf serebro ginjal
1 c374377 1 2 2 2 1 1 2 C373947 7 2 2 1 2 2 3 484757 1 2 2 1 2 2 4 c377238 7 2 2 2 1 2 5 c383888 1 2 2 2 2 2 6 c386336 7 2 2 2 2 2 7 c371174 1 2 2 1 2 2 8 b371770 1 2 2 2 2 1 9 c387630 7 2 2 1 2 1 10 c366531 1 2 2 2 2 2 11 c377370 1 2 2 2 2 2 12 c374186 1 2 2 2 2 2 13 c384952 7 2 2 2 2 1 14 c430487 1 2 2 2 1 1 15 c392798 1 2 1 2 1 2 16 b377418 2 2 2 2 1 2 17 c398081 10 2 2 2 1 2 18 c052585 4 2 2 2 2 2 19 b148605 1 2 2 2 1 2 20 c268084 1 2 2 2 2 1 21 c124793 5 2 2 2 2 2 22 c427502 4 2 2 2 2 2 23 c428852 1 2 2 1 2 2 24 c421710 1 2 2 2 1 2 25 c214179 1 2 2 2 2 1 26 c400199 1 2 2 2 2 1 27 c397469 1 2 2 2 1 2 28 c225469 1 2 2 2 2 2 29 c397568 1 2 2 2 2 1 30 c243988 9 2 2 2 2 2 31 c426718 2 2 2 1 2 2 32 c273637 1 2 2 2 2 2 33 c416097 1 2 1 1 2 2 34 c417197 1 2 2 1 2 2
No
Nomer
cm Terapi Keganasan Liver Chf Serebro ginjal
35 c427437 1 2 2 1 2 2 36 c404497 1 2 2 2 2 2 37 c428997 1 2 2 1 2 1 38 c291567 1 2 2 2 2 2 39 c204117 1 2 2 1 2 2 40 c422706 1 2 2 1 2 2 41 c340066 1 1 2 2 2 2 41 c122806 5 2 1 2 2 2 43 b274925 1 2 2 2 2 2 44 c414835 1 2 2 2 2 2 45 c205875 1 1 2 2 2 2 46 c424255 1 2 2 2 1 2 47 c385434 1 2 2 2 2 2 48 c287864 1 2 2 1 2 1 49 c393824 1 2 2 2 2 2 50 c429414 1 2 2 2 2 2 51 c389513 1 1 2 2 2 2 52 c396233 1 2 2 2 2 2 53 c109693 1 2 2 1 2 2 54 c422472 8 2 2 2 2 2 55 c343112 1 2 2 2 2 2 56 c418952 2 2 2 2 2 2 57 b428322 7 2 2 1 2 2 58 c413152 1 2 2 1 2 2 59 c404311 1 2 2 2 2 2 60 b186461 1 2 2 1 2 2 61 c415130 1 2 2 2 2 2 62 b369240 1 2 2 1 2 2 63 c426800 1 2 2 2 2 2 63 c364230 3 2 2 2 2 2 65 c428429 6 2 2 2 2 2 66 c396968 1 2 2 2 2 2 67 c384489 1 2 2 2 2 2 68 c083541 1 2 2 1 2 2
Lampiran 6. Daftar tilik penelusuran rekam medik Nama Usia Nomer registri Jenis kelamin Tempat perawatan Skoring PSI
Karakteristik Pasien Poin skor Skor
Faktor Demografi
Usia laki-laki Usia
Usia wanita Usia-10
Tinggal di rumah perawatan 10
Penyakit Komorbid
Keganasan 30
Penyakit liver 20
Gagal jantung kongestif 10
Penyakit serebrovaskuler 10
Penyakit ginjal 10
Temuan Pemeriksaan Fisik
Penurunan kesadaran 20
Laju pernapasan ≥ 30 x per menit 20 Tekanan darah sistolik <90 mmHg 20 Suhu < 35 oC / ≥40 oC 15
Nadi ≥ 125 x per menit 10
Temuan Laboratorium
pH <7,35 30
BUN>11mmol/L atau ≥30mg/dL 20
Natrium <130mmol/L 20
Gula darah >14 mmol/L atau
≥250mg/dL 10
Hematokrit <30% 10
p02 <60mmHg 10
Efusi pleura 10
Total skor PSI Derajat keparahan
Skoring CURB-65
Karakteristik Poin Skor Skor
Penurunan kesadaran 1
Urea nitrogen darah > 20 mg per dL (7.14 mmol per L)
1 Laju pernapasan ≥ 30 x per menit 1 Tekanan darah (sistolik < 90 mm Hg
atau diastolik ≤ 60 mm Hg) 1
Usia ≥ 65 tahun 1
Total skor CURB-65 Derajat keparahan
Lampiran 8. Biodata Mahasiswa
Identitas
Nama : Nina Widasari
NIM : 22010110120119
Tempat / tanggal lahir : Takengon, 3 Juli 1992 Jenis Kelamin : Perempuan
Alamat : Jl. Azalea IV no. 8U Kompleks Cemara Asri Medan
Nomor HP : 083838808789
E-mail : ninawidasariyanis@gmail.com
Riwayat Pendidikan Formal
1. SD : 1998 Lulus tahun : 2004
2. SMP : 2004 Lulus tahun : 2007
3. SMA : 2007 Lulus tahun : 2010
4. FK UNDIP : Masuk tahun 2010
Keanggotan Organisasi
